Compare IXHL & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IXHL | BHST |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | Australia | Canada |
| Employees | N/A | 87 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.6M | 104.2M |
| IPO Year | 2024 | N/A |
| Metric | IXHL | BHST |
|---|---|---|
| Price | $3.98 | $4.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 5.4M | 18.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,000.00 | N/A |
| Revenue This Year | N/A | $116.40 |
| Revenue Next Year | N/A | $55.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $4.27 |
| 52 Week High | $5.17 | $12.80 |
| Indicator | IXHL | BHST |
|---|---|---|
| Relative Strength Index (RSI) | 86.14 | 37.89 |
| Support Level | $0.32 | $4.27 |
| Resistance Level | N/A | $5.04 |
| Average True Range (ATR) | 0.20 | 0.29 |
| MACD | 0.45 | 0.00 |
| Stochastic Oscillator | 75.88 | 21.95 |
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.